Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Under 4 now, would not be surprised at all to see it

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton May 20, 2021 11:06pm

158 Views

Post# 33246123

RE:RE:RE:Under 4 now, would not be surprised at all to see it

the days of delays and stagnation are coming to an end.
More investors - raises equates to more pressure to deliver and more high vis board members supporting but also putting pressure on Dan and team to meet timelines / move more quickly. My faith is more in Joe as he has been there, done that and can help keep the pace needed for ph3

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success